ftInvstr
MEDANTA · Healthcare ₹1472.5 +3.13% Mkt Cap ₹39597 Cr

MEDANTA

Healthcare Medical Care Facilities
₹1472.5
+3.13% today · 30d +1.34%
as of 2026-09-04
Price · Daily Candles
“Medanta shines in profitability, but FIIs pare holdings as DIIs step up.”
Global Health (Medanta) recorded strong quarterly growth with net profit up 39.73% YoY to ₹142 Cr and revenue increasing by 24.46% YoY to ₹1,159 Cr in Q4 2026. The company maintains its 'Strong' growth and 'High' profitability scores, yet FII holdings decreased by 0.38% QoQ, coinciding with a 0.76% increase from DIIs.
BULL CASE
+Q4 2026 net profit surged +39.73% YoY to ₹142 Cr, outperforming revenue growth.
+Quarterly revenue saw a significant increase of +24.46% YoY, reaching ₹1,159 Cr.
+Annual net profit CAGR for the last 5 years stands at an impressive 80.62%, indicating strong sustained growth.
+The company boasts high profitability with a TTM profit margin of 12.62% and ROCE of 17.0%.
BEAR CASE
Free cash flow remains negative at -₹124 Cr, resulting in a -0.37% FCF yield.
FIIs reduced their stake by 0.38% QoQ, bringing their total holding to 10.15%.
Operating profit margin declined by 2.49% YoY in Q4 2026, despite revenue growth.
The share price is 15.7% off its 52-week high of ₹1456.5, trading at ₹1227.9.
⟳ What Changed
₹ Latest Earnings · Q ending 2026-06-30
REVENUE
₹1304 Cr
+26.5% YoY
NET PROFIT
₹157 Cr
-1.09% YoY
OPM
23.29%
-0.24pp YoY
EPS
₹5.91
PE 59.62
Intrinsic value · DCF: N/A — Company is currently free-cash-flow negative (-0.3% of mktcap). DCF assumes a going concern generating positive cash flow; a meaningful intrinsic value can only be computed once FCF turns positive. Use the Strategy Fit and ML sections instead.
◇ Sector Position
With a TTM PE of 59.62 and ROCE of 17.0%, Medanta trades at a more attractive valuation than peers like Apollo Hospitals (PE 82.13, ROCE 20.26%) and Fortis (PE 94.26, ROCE 13.4%), while offering a better ROCE than Max Healthcare (ROCE 14.44%).
PEERPEROCE %
MEDANTA59.6217.0
APOLLOHOSP82.1320.26
MAXHEALTH67.0714.44
FORTIS94.2613.4
+ 2 more peers — sign in to view
ML Forward Growth Predictions 🔒

9 ML-predicted forward-growth ranks across sales, EBIT, and FCF.

Sign up freeSign in
64
SCORE / 100
Overall
6-axis composite of the sections below.
Performance STRONG 75
Valuation STRETCHED 20
Growth STRONG 73
Profitability HIGH 78
Technicals NEUTRAL 67
Risk LOW 70
Key Stats
TTM PE
59.62
P/B
8.92
52W HIGH
₹1544.0
OFF HIGH
-4.63%
DIV YIELD
0.04%
MKT CAP
₹39597 Cr
◉ Active Signals
MACDNeutral-2.2448
RSI(14)Neutral56.19
Near 52W HighBullish-4.63
Street Consensus
17 analysts
₹1419.06
mean target
Low ₹1210.0Now ₹1472.5High ₹1570.0
⧉ Strategy Fit 🔒

See which of ftInvstr's 50+ strategies hold MEDANTA and at what entry.

Sign up freeSign in